Introduction: C-reactive protein (CRP) and Bedside Index for Severity in Acute Pancreatitis (BISAP) have been used in early risk assessment of patients with AP.
Objectives: We evaluated prognostic accuracy of CRP at 24 hours after hospital admission (CRP24) for in-hospital mortality (IM) in AP individually and with BISAP.
Materials And Methods: This retrospective cohort study included 134 patients with AP from a Portuguese hospital in 2009-2010. Prognostic accuracy assessment used area under receiver-operating characteristic curve (AUC), continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
Results: Thirteen percent of patients had severe AP, 26% developed pancreatic necrosis, and 7% died during index hospital stay. AUCs for CRP24 and BISAP individually were 0.80 (95% confidence interval (CI) 0.65-0.95) and 0.77 (95% CI 0.59-0.95), respectively. No patients with CRP24 <60 mg/l died ( = 0.027; negative predictive value 100% (95% CI 92.3-100%)). AUC for BISAP plus CRP24 was 0.81 (95% CI 0.65-0.97). Change in NRI (42.4%; 95% CI, 24.9-59.9%) resulted in positive overall NRI (31.3%; 95% CI, -36.4% to 98.9%), but IDI was negligible (0.004; 95% CI, -0.007 to 0.014).
Conclusions: CRP24 revealed good prognostic accuracy for IM in AP; its main role may be the selection of lowest risk patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580176 | PMC |
http://dx.doi.org/10.1016/j.jpge.2015.03.002 | DOI Listing |
Radiol Med
January 2025
Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong.
Purpose: Bodyweight loss is commonly found in Nasopharyngeal Carcinoma patients during Concurrent Chemo-radiotherapy (CCRT) and has implications for treatment decisions. However, the prognostic value of this weight loss remains uncertain. We addressed it by proposing a novel index Weight Censorial Score (WCS) that characterizes the patient-specific CCRT response on actual to estimated weight loss.
View Article and Find Full Text PDFFront Cardiovasc Med
January 2025
Department of Artificial Intelligence and Informatics, Mayo Clinic, Jacksonville, FL, United States.
Background: Effective management of dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) implantation is crucial for preventing adverse events. Traditional prognostic tools, such as rule-based methods or Cox regression, despite their widespread use and ease, tend to yield moderate predictive accuracy within predetermined timeframes. This study introduces a new contrastive learning-based approach to enhance prediction efficacy over multiple time intervals.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Background: Patients with pancreatic ductal adenocarcinoma (PDAC) face a highly unfavorable outcome and have a poor response to standard treatments. Immunotherapy, especially therapy based on natural killer (NK) cells, presents a promising avenue for the treatment of PDAC.
Aims: This research endeavor seeks to formulate a predictive tool specifically designed for PDAC based on NK cell-related long non-coding RNA (lncRNA), revealing new molecular subtypes of PDAC to promote personalized and precision treatment.
ERJ Open Res
January 2025
Department of Smoking and COPD Research, National Institute of Respiratory Diseases, Mexico City, Mexico.
Background: COPD ranks as the third leading global cause of mortality. Despite the widespread use of the BODE index and its variants for mortality prediction, their accuracy may be affected by factors like ethnicity, altitude and regional disparities. This study aimed to assess a new altitude-adapted prognostic index in COPD patients at moderate altitudes compared with the BODE and other mortality predictors.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Department of Neurological Function Examination, Affiliated Hospital of Hebei University, Baoding, China.
Background: Lower-grade glioma (LGG) exhibits significant heterogeneity in clinical outcomes, and current prognostic markers have limited predictive value. Despite the growing recognition of histone modifications in tumor progression, their role in LGG remains poorly understood. This study aimed to develop a histone modification-based risk signature and investigate its relationship with drug sensitivity to guide personalized treatment strategies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!